How should drooling caused by Zyprexa (olanzapine) be managed?

Management of Zyprexa (Olanzapine)-Induced Drooling

For olanzapine-induced drooling (sialorrhea), start with non-pharmacological measures including chewing sugar-free gum and using a towel over the pillow at night, then escalate to ipratropium sublingual spray or low-dose amisulpride (50 mg twice daily) as first-line pharmacological interventions if conservative measures fail.

Understanding the Problem

Drooling (sialorrhea) is a recognized adverse effect of olanzapine, though it occurs less frequently than with clozapine. The FDA label for Zyprexa does not specifically list drooling as a common side effect 1, but clinical experience and research confirm its occurrence 2, 3. This side effect results from impaired swallowing coordination rather than true hypersalivation, combined with the anticholinergic properties of the medication creating a paradoxical effect 3.

Stepwise Management Approach

Step 1: Non-Pharmacological Interventions

Begin with conservative measures 4:

• Chewing sugar-free gum during the day to stimulate swallowing
• Placing a towel over the pillow when sleeping to manage nocturnal drooling
• Sleep positioning: Elevate the head of the bed
• Assess timing: Nocturnal choking increases aspiration pneumonia risk and requires more aggressive intervention

Step 2: Pharmacological Management

If conservative measures fail after 1-2 weeks, consider pharmacological options based on the most recent evidence:

First-line pharmacological options 4:

• Ipratropium sublingual spray: Low side-effect profile, works locally as an anticholinergic
• Amisulpride 50 mg twice daily: Particularly effective when positive symptoms are controlled and you want to avoid additional anticholinergic burden

Alternative options to avoid 4:

• Hyoscine lozenges and diphenhydramine can worsen constipation (already a concern with olanzapine)
• Atropine sublingual drops carry overdose lethality risk

Step 3: Dose Optimization

Consider olanzapine dose reduction 4:

• If psychotic symptoms are well-controlled, gradually reduce the olanzapine dose while remaining within the therapeutic range
• The FDA-approved dosing range is 5-20 mg daily 1
• Lower doses may reduce drooling while maintaining efficacy

Step 4: Medication Switch

If drooling persists despite the above measures:

• Consider switching to aripiprazole if clinically appropriate 4
• Aripiprazole has been shown to reduce various olanzapine-related side effects including sialorrhea

Critical Monitoring Points

Watch for complications of drooling 5:

• Perioral chapping and skin breakdown
• Dehydration (paradoxically, from constant saliva loss)
• Social stigmatization affecting quality of life
• Nocturnal aspiration risk: This is the most serious complication requiring urgent intervention

Assess constipation status 4:

• Olanzapine commonly causes constipation
• Adding anticholinergic agents for drooling will worsen this
• Prophylactic laxatives (docusate plus senna, augmented by macrogols) should be considered before adding anticholinergics

Common Pitfalls to Avoid

1. Do not add multiple anticholinergic agents: This worsens constipation and cognitive effects, particularly in elderly patients 6, 4

2. Avoid atropine drops: Despite effectiveness, the lethality risk in overdose makes this inappropriate for outpatient management 4

3. Do not ignore the underlying cause: Ensure drooling is truly medication-related and not from other neurological conditions or concurrent medications 5

4. Do not use systemic anticholinergics as first-line: These have more side effects than local treatments like ipratropium spray 3

Special Populations

Elderly patients 6, 1:

• Olanzapine carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis
• Use lower doses (2.5 mg starting dose)
• Be especially cautious with anticholinergic burden
• Monitor for orthostatic hypotension, which olanzapine already causes 7

Patients with metabolic concerns 1:

• Olanzapine causes weight gain and metabolic effects
• Document baseline weight, glucose, and lipids
• Consider whether drooling severity justifies continuing olanzapine versus switching to an agent with better metabolic profile

Documentation and Follow-up

• Use validated scales like the Drooling Severity and Frequency Scale or Toronto Nocturnal Hypersalivation Scale to objectively track severity 4
• Reassess at 2-week intervals after each intervention
• Document impact on quality of life and social functioning
• Monitor for aspiration symptoms (cough, recurrent pneumonia)